Instil Bio Sees 26% Surge Amid NSCLC Trial Developments
By ATTN Desk · Editorial oversight: Sean Han
INSTIL BIO INC (TIL)
Introduction
INSTIL BIO INC (NASDAQ: TIL, Korean name: 인스틸 바이오) is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. As of May 28, 2025, shares closed at $30.52, reflecting a 26.09% increase on volume of 240,851.
Corporate Profile
- Industry: Biotechnology (Oncology)
- Company Size: 11–50 employees
- Headquarters: Dallas, Texas
- Leadership:
- Bronson Crouch, Chief Executive Officer
- Over 15 years of experience in biotechnology and pharmaceuticals
- Managing Partner, Curative Ventures
- Previous investments include CoStim Pharmaceuticals (acquired by Novartis in 2014), Peloton Therapeutics (acquired by Merck in 2019), TCR2 Therapeutics, and iTeos Therapeutics
- Bronson Crouch, Chief Executive Officer
Recent Developments and News
- January 14, 2025 – ImmuneOnco Biopharmaceuticals (Shanghai) dosed the first patient in a Phase 1b/2 trial of IMM2510/SYN-2510 in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) in China.
- 2H 2025 – Initial clinical data from the China NSCLC trial is expected.
- 2H 2025 – Planned initiation of a first-line NSCLC trial in the U.S. with IMM2510/SYN-2510 combined with chemotherapy, pending regulatory approvals.
- May 22, 2025 – Filed Form 8-K (Items 7.01, 9.01) with the SEC.
- May 27, 2025 – Filed Form 8-K (Items 7.01, 8.01, 9.01) with the SEC.
- May 15, 2025 – Amendment to Schedule 13G/A reported no beneficial ownership by reporting persons (Boxer Asset Management Inc., Joe Lewis, MVA Investors, LLC).
Financial and Strategic Analysis
Stock Performance
| Metric | Value |
|---|---|
| Closing Price (5/28) | $30.52 |
| Daily Change | +26.09% |
| Day’s Range | $22.66 – $31.46 |
| 52-Week Range | $9.62 – $92.00 |
| Volume | 240,851 |
| Avg. Volume | 160,635 |
| Market Cap | $197.96 M |
Key Financial Metrics (TTM/mrq)
- Net Loss: $78.03 M
- Diluted EPS: –$11.97
- Profit Margin: 0.00%
- Total Cash: $103.65 M
- Total Debt/Equity: 58.16%
- Levered Free Cash Flow: –$130.54 M
- 1-Year Target Estimate: $118.67
Strategic Considerations
- Pipeline Focus: SYN-2510 (IMM2510), a PD-L1×VEGF bispecific antibody designed with a multi-ligand VEGF trap and enhanced antibody-dependent cellular cytotoxicity (ADCC).
- Collaborations: Partnership with ImmuneOnco enhances clinical trial efforts in China and supports planned U.S. expansion.
- Cash Runway: Company holds $103.65 M in cash, with negative free cash flow indicating a reliance on future financing or partnerships.
- Valuation: Market capitalization near $198 M suggests early-stage development with upcoming catalysts.
Market Position and Industry Context
- Operates in the immuno-oncology segment, developing treatments that target solid tumors, specifically focusing on NSCLC.
- Competes with established biopharmaceutical companies and other clinical-stage developers of bispecific antibodies.
- Utilizes an in-licensing model for the acquisition and advancement of novel therapeutic candidates in areas with unmet medical needs.
tl;dr
- As of May 28, 2025, share price is $30.52 (+26.09%).
- On January 14, 2025, the first patient was dosed in a Phase 1b/2 trial in China for IMM2510/SYN-2510 combined with chemotherapy; initial data is expected in 2H 2025.
- A U.S. trial for first-line NSCLC is planned for 2H 2025.
- Cash balance is $103.65 M; net loss for the trailing twelve months is $78.03 M.
- 1-year consensus target is $118.67, reflecting expectations for the pipeline.